Eton Pharmaceuticals (ETON) Receivables (2019 - 2025)

Eton Pharmaceuticals has disclosed Receivables across 7 years of filings, most recently posting $11.8 million for Q4 2025.

• Receivables for Q4 2025 came in at $11.8 million, up 119.31% year-over-year; the trailing twelve-month figure through Dec 2025 was $11.8 million (up 119.31% YoY), and the FY2025 annual result was $11.8 million, up 119.31% from the prior year.
• Receivables came in at $11.8 million for Q4 2025 at Eton Pharmaceuticals, up from $5.0 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $11.8 million in Q4 2025 to a low of $300000.0 in Q1 2021.
• The 5-year median for Receivables is $3.5 million (2023), against an average of $3.5 million.
• Across the five-year window, Receivables surged 10316.67% in 2021 and sank 62.96% in 2022, its largest moves.
• Eton Pharmaceuticals' Receivables stood at $5.0 million in 2021, then sank by 62.96% to $1.9 million in 2022, then surged by 84.18% to $3.4 million in 2023, then jumped by 57.17% to $5.4 million in 2024, then soared by 119.31% to $11.8 million in 2025.
• The last three Receivables figures came in at $11.8 million (Q4 2025), $5.0 million (Q3 2025), and $5.0 million (Q2 2025), per Business Quant data.